Clinical Trial

Nemtabrutinib, Bortezomib, and Rituximab for WM

Name: Nemtabrutinib, Bortezomib, and Rituximab for WM — clinical trial record (NCT07464210)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase II (2 parts), open-label, single arm, multicenter study to evaluate the efficacy and safety of nemtabrutinib in combination with bortezomib and rituximab

Trial Details

NCT Number	NCT07464210
Lead Sponsor	Seoul National University Hospital
Conditions	Waldenstrom Macroglobulinemia
Enrollment	19 participants
Start Date	2026-06-01
Primary Completion	2029-08-01 (estimated)
Study Completion	2030-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-11